Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Maschmeyer

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
Annals of Hematology|April 13, 2021
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)Annika Y Classen, Larissa Henze, Marie von Lilienfeld-Toal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Annals of Hematology|October 15, 2008
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Angelika Böhme, Markus Ruhnke, et al.
The Oncologist|June 17, 2024
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric massStefan Habringer, Jana Ihlow, Karsten Kleo, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2020
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registrySebastian Birndt, Thomas Schenk, Babett Heinevetter, et al.
Oncology Research and Treatment|June 1, 2025
Guidelines of Onkopedia: What Is New?Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncologyDamian T Rieke, Michael Bitzer, Annalen Bleckmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
Annals of Hematology|April 13, 2021
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)Annika Y Classen, Larissa Henze, Marie von Lilienfeld-Toal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Annals of Hematology|October 15, 2008
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Angelika Böhme, Markus Ruhnke, et al.
The Oncologist|June 17, 2024
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric massStefan Habringer, Jana Ihlow, Karsten Kleo, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2020
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registrySebastian Birndt, Thomas Schenk, Babett Heinevetter, et al.
Oncology Research and Treatment|June 1, 2025
Guidelines of Onkopedia: What Is New?Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncologyDamian T Rieke, Michael Bitzer, Annalen Bleckmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Pageof 10